Dilip S. Shanghvi, promoter of sun pharma advanced research co , has filed a regulatory declaration with the National Stock Exchange and BSE Limited, confirming no encumbrance on company shares as of March 31, 2026. The declaration was submitted on April 02, 2026, in compliance with SEBI regulations governing substantial acquisitions and takeovers.

Regulatory Compliance Declaration

The declaration was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any encumbrances created on shares of the target company during specified periods.

Share Encumbrance Status

Shanghvi confirmed that as of March 31, 2026, neither he nor the promoter group and persons acting in concert have created any encumbrance, directly or indirectly, on the shares of Sun Pharma Advanced Research Company Limited. The declaration specifically noted that no new encumbrances were made other than those already disclosed during the financial year.

Stock Exchange Communication

The formal declaration was addressed to both major Indian stock exchanges where the company's shares are listed. The communication was sent to the National Stock Exchange of India Limited and BSE Limited, ensuring compliance with disclosure requirements across all trading platforms.

The declaration serves as an important transparency measure, providing investors and regulatory authorities with current information about promoter shareholding patterns and any potential encumbrances that could affect share ownership or voting rights.

Sun Pharmaceutical Industries Limited has filed its quarterly confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The regulatory submission demonstrates the company's continued compliance with securities market regulations.

Regulatory Compliance Filing

The company submitted the confirmation certificate dated April 03, 2026, pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The certificate was received from MUFG Intime India Private Limited, which serves as the company's registrar and share transfer agent.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialization during the quarter ended March 31, 2026, were properly processed according to regulatory requirements. The registrar verified that:

• Securities received for dematerialization were confirmed or rejected to depositories within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Depositories' names were substituted in the register of members as registered owners
• All securities comprised in the certificates have been listed on relevant stock exchanges

Corporate Governance

The filing was signed by Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited. The submission was made to National Stock Exchange of India Limited and BSE Limited, ensuring comprehensive regulatory compliance across all relevant market infrastructure institutions.

This quarterly filing represents part of the company's ongoing regulatory obligations and demonstrates adherence to SEBI's depositories regulations framework.